Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Orum moving CD123-targeted DAC into first-in-human testing against AML

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

Orum Therapeutics received FDA clearance to start first-in-human Phase I trials of ORM-1153, a novel CD123-targeted degrader-antibody conjugate for relapsed or refractory acute myeloid leukemia and other hematologic malignancies, planned to begin by the end of 2026.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

Orum's FDA clearance opens a clinical testing door for novel degrader-antibody conjugates in AML, signalling a rare chance to lead in targeted cancer degradation approaches. You can now plan your product strategy around emerging DAC modalities with real patient data on the horizon.

◆ Coverage

3 sources · 24 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-clearanceamldacclinical-trialstargeted-therapy